A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Sampson, Valerie B ^a   Gorlick, Richard ^b   Kamara, Davida ^a   Kolb, E Anders ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Complete response; Event free survival; Maintained complete response; Osteosarcoma; Partial response; Pediatric preclinical testing program; Progressive disease; Progressive disease with growth delay

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL) AMINO] PYRROLO [2, 1 F] [1, 2, 4] TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 4 [2 (4 AMINO 1, 2, 5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO [4, 5 C] PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL) PYRAZOLO [3, 4 D] PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL) PYRAZOLO [3, 4 D] PYRIMIDINE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALISERTIB; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; AT 13387; AZD 8055; CEDIRANIB; CIXUTUMUMAB; DASATINIB; DINACICLIB; ERIBULIN; FIGITUMUMAB; GSK 923295A; IMATINIB; LAPATINIB; NAVITOCLAX; RAPAMYCIN; RG 7112; ROBATUMUMAB; SELUMETINIB; SERDEMETAN; SORAFENIB; SUNITINIB; TEPROTUMUMAB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; EWING SARCOMA; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NONHUMAN; OSTEOSARCOMA; PEDIATRICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

EID: 84885779270     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00132     Document Type: Article

References (110)

1. Aguilera, D. G., and Tsimberidou, A. M. (2009). Dasatinib in chronic myeloid leukemia: a review. Ther. Clin. Risk. Manag. 5, 281-289.
2. Akiyama, T., Dass, C. R., and Choong, P. F. (2008). Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol. Cancer Ther. 7, 3461-3469. doi:10.1158/1535-7163.MCT-08-0530
3. Anderson, P., Kopp, L., Anderson, N., Cornelius, K., Herzog, C., Hughes, D., et al. (2008). Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin. Investig. Drugs 17, 1703-1715. doi:10.1517/13543784.17.11.1703
4. Aplenc, R., Blaney, S. M., Strauss, L. C., Balis, F. M., Shusterman, S., Ingle, A. M., et al. (2012). Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children's Oncology Group Phase I Consortium. J. Clin. Oncol. 29, 839-844. doi:10.1200/JCO.2010.30.7231
5. Batra, V., Maris, J. M., Kang, M. H., Reynolds, C. P., Houghton, P. J., Alexander, D., et al. (2012). Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 59, 749-752. doi:10.1002/pbc.23364
6. Benassi, M. S., Molendini, L., Gamberi, G., Magagnoli, G., Ragazzini, P., Gobbi, G. A., et al. (2001). Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer 92, 3062-3067. doi:10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X
7. Blay, J., Chawla, S. P., Ray-Coquard, I. L., Le Cesne, A., Staddon, A. P., and Milhem, M. M. (2011). Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J. Clin. Oncol. 29(Suppl.), abstr. 10005.
8. Bond, M., Bernstein, M. L., Pappo, A., Schultz, K. R., Krailo, M., Blaney, S. M., et al. (2008). A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group Study. Pediatr. Blood Cancer 50, 254-258. doi:10.1002/pbc.21132
9. Bromberg-White, J. L., Andersen, N. J., and Duesbery, N. S. (2012). MEK genomics in development and disease. Brief Funct. Genomics 11, 300-310.
10. Cannon, C. M., Pozniak, J., Scott, M. C., Ito, D., Gorden, B. H., Graef, A. J., et al. (2013). Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors. Vet. Comp. Oncol. doi:10.1111/vco.12018 [Epub ahead of print].
11. Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Reynolds, C. P., et al. (2010a). Initial testing of topotecan by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 707-715. doi:10.1002/pbc.22352
12. Carol, H., Morton, C. L., Gorlick, R., Kolb, E. A., Keir, S. T., Reynolds, C. P., et al. (2010b). Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr. Blood Cancer 55, 1329-1337. doi:10.1002/pbc.22710
13. Carol, H., Reynolds, C. P., Kang, M. H., Keir, S. T., Maris, J. M., Gorlick, R., et al. (2013). Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer doi:10.1002/pbc.24235
14. Casaletto, J. B., and McClatchey, A. I. (2012). Spatial regulation of receptor tyrosine kinases in development and cancer. Nat. Rev. Cancer 12, 387-400. doi:10.1038/nrc3277
15. Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., et al. (2012). Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J. Clin. Oncol. 30, 78-84. doi:10.1200/JCO.2011.35.6329
16. Chen, D. J., and Huerta, S. (2009). Smac mimetics as new cancer therapeutics. Anticancer Drugs 20, 646-658. doi:10.1097/CAD.0b013e32832ced78
17. Creedon, H., and Brunton, V. G. (2012). Src kinase inhibitors: promising cancer therapeutics? Crit. Rev. Oncog. 17, 145-159. doi:10.1615/CritRevOncog.v17.i2.20
18. Deeks, E. D., and Keating, G. M. (2006). Sunitinib. Drugs 66, 2255-2266; discussion 2267-2268. doi:10.2165/00003495-200666170-00007
19. Diaz-Montero, C. M., Wygant, J. N., and McIntyre, B. W. (2006). PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur. J. Cancer 42, 1491-1500. doi:10.1016/j.ejca.2006.03.007
20. Dubois, S. G., Shusterman, S., Ingle, A. M., Ahern, C. H., Reid, J. M., Wu, B., et al. (2011). Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Clin. Cancer Res. 17, 5113-5122. doi:10.1158/1078-0432.CCR-11-0237
21. DuBois, S. G., Shusterman, S., Reid, J. M., Ingle, A. M., Ahern, C. H., Baruchel, S., et al. (2012). Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Cancer Chemother. Pharmacol. 69, 1021-1027. doi:10.1007/s00280-011-1798-2
22. Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., et al. (2012). Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 2545-2551. doi:10.1200/JCO.2011.37.4546
23. Ferrari, S., and Palmerini, E. (2007). Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr. Opin. Oncol. 19, 341-346. doi:10.1097/CCO.0b013e328122d73f
24. Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., et al. (2010). Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group Phase I Consortium Report. J. Clin. Oncol. 28, 3623-3629. doi:10.1200/JCO.2009.25.9119
25. Fox, E., Aplenc, R., Bagatell, R., Chuk, M. K., Dombi, E., Goodspeed, W., et al. (2010). A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 28, 5174-5181. doi:10.1200/JCO.2010.30.9674
26. Fu, W., Ma, L., Chu, B., Wang, X., Bui, M. M., Gemmer, J., et al. (2011). The cyclin-dependent kinase inhibitor SCH 727965 (dinaciclib) induces the apoptosis of osteosarcoma cells. Mol. Cancer Ther. 10, 1018-1027. doi:10.1158/1535-7163.MCT-11-0167
27. Garrett, C. R., Coppola, D., Wenham, R. M., Cubitt, C. L., Neuger, A. M., Frost, T. J., et al. (2011). Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest. New Drugs 29, 1381-1389. doi:10.1007/s10637-010-9479-2
28. Glade Bender, J. L., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., et al. (2008). Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 26, 399-405. doi:10.1200/JCO.2007.11.9230
29. Gorlick, R., Kolb, E. A., Houghton, P. J., Morton, C. L., Phelps, D., Schaiquevich, P., et al. (2009). Initial testing (stage 1) of lapatinib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 53, 594-598. doi:10.1002/pbc.21989
30. Gorlick, R., Maris, J. M., Houghton, P. J., Lock, R., Carol, H., Kurmasheva, R. T., et al. (2012a). Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 59, 518-524. doi:10.1002/pbc.23412
31. Gorlick, R., Kolb, E. A., Houghton, P. J., Morton, C. L., Neale, G., Keir, S. T., et al. (2012b). Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 59, 1266-1274. doi:10.1002/pbc.24073
32. Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D'Ambrosio, L., Pignochino, Y., et al. (2012). A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group Study. Ann. Oncol. 23, 508-516. doi:10.1093/annonc/mdr151
33. Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., Chen, M., et al. (2011). mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 71, 3246-3256. doi:10.1158/0008-5472.CAN-10-4058
34. Guo, W., Gorlick, R., Ladanyi, M., Meyers, P. A., Huvos, A. G., Bertino, J. R., et al. (1999). Expression of bone morphogenetic proteins and receptors in sarcomas. Clin. Orthop. Relat. Res. 365, 175-183. doi:10.1097/00003086-199908000-00023
35. Hawkins, D. S., Bradfield, S., Whitlock, J. A., Krailo, M., Franklin, J., Blaney, S. M., et al. (2006). Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr. Blood Cancer 47, 790-794. doi:10.1002/pbc.20739
36. Hingorani, P., Zhang, W., Gorlick, R., and Kolb, E. A. (2009). Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin. Cancer Res. 15, 3416-3422. doi:10.1158/1078-0432.CCR-08-1657
37. Hotta, T., Suzuki, H., Nagai, S., Yamamoto, K., Imakiire, A., Takada, E., et al. (2003). Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J. Orthop. Res. 21, 949-957. doi:10.1016/S0736-0266(03)00062-7
38. Houghton, P. J., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Morton, C. L., et al. (2012a). Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 191-199. doi:10.1002/pbc.22935
39. Houghton, P. J., Kang, M. H., Reynolds, C. P., Morton, C. L., Kolb, E. A., Gorlick, R., et al. (2012b). Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58, 636-639. doi:10.1002/pbc.23167
40. Houghton, P. J., Lock, R., Carol, H., Morton, C. L., Gorlick, R., Anders Kolb, E., et al. (2012c). Testing of the topoisomerase 1 inhibitor Genz-644282 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58, 200-209. doi:10.1002/pbc.23016
41. Houghton, P. J., Morton, C. L., Gorlick, R., Kolb, E. A., Keir, S. T., Reynolds, C. P., et al. (2010a). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 921-926. doi:10.1002/pbc.22367
42. Houghton, P. J., Morton, C. L., Gorlick, R., Lock, R. B., Carol, H., Reynolds, C. P., et al. (2010b). Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol. Cancer Ther. 9, 101-112. doi:10.1158/1535-7163.MCT-09-0952
43. Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., Lock, R., Carol, H., et al. (2008a). Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 50, 799-805. doi:10.1002/pbc.21296
44. Houghton, P. J., Morton, C. L., Kolb, E. A., Lock, R., Carol, H., Reynolds, C. P., et al. (2008b). Initial testing (stage 1) of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 50, 37-45. doi:10.1002/pbc.21214
45. Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., et al. (2007). The Pediatric Preclinical Testing Program: description of models and early testing results. Pediatr. Blood Cancer 49, 928-940. doi:10.1002/pbc.21078
46. Jaffe, N., Patel, S. R., and Benjamin, R. S. (1995). Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol. Oncol. Clin. North Am. 9, 825-840.
47. Juergens, H., Daw, N. C., Geoerger, B., Ferrari, S., Villarroel, M., Aerts, I., et al. (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29, 4534-4540. doi:10.1200/JCO.2010.33.0670
48. Kang, M. H., Reynolds, C. P., Houghton, P. J., Alexander, D., Morton, C. L., Kolb, E. A., et al. (2012). Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 59, 185-188. doi:10.1002/pbc.23154
49. Keating, G. M., and Santoro, A. (2009). Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69, 223-240. doi:10.2165/00003495-200969020-00006
50. Keir, S. T., Maris, J. M., Lock, R., Kolb, E. A., Gorlick, R., Carol, H., et al. (2010). Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 55, 1126-1133. doi:10.1002/pbc.22712
51. Keshelava, N., Houghton, P. J., Morton, C. L., Lock, R. B., Carol, H., Keir, S. T., et al. (2009). Initial testing (stage 1) of vorinostat (SAHA) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 53, 505-508. doi:10.1002/pbc.21988
52. Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Lock, R. B., Tajbakhsh, M., et al. (2008a). Initial testing of dasatinib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 50, 1198-1206. doi:10.1002/pbc.21450
53. Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Lock, R., Carol, H., et al. (2008b). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 50, 1190-1197. doi:10.1002/pbc.21450
54. Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Neale, G., Keir, S. T., et al. (2010). Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 55, 668-677. doi:10.1002/pbc.22576
55. Kolb, E. A., Gorlick, R., Lock, R., Carol, H., Morton, C. L., Keir, S. T., et al. (2011). Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr. Blood Cancer 56, 595-603. doi:10.1002/pbc.22741
56. Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Lock, R., Carol, H., et al. (2012a). Initial testing (stage 1) by the Pediatric Preclinical Testing Program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr. Blood Cancer 58, 815-818. doi:10.1002/pbc.23290
57. Kolb, E. A., Gorlick, R., Maris, J. M., Keir, S. T., Morton, C. L., Wu, J., et al. (2012b). Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58, 729-735. doi:10.1002/pbc.23157
58. Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Carol, H., Lock, R., et al. (2013). Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer. [Epub ahead of print]. doi:10.1002/pbc.24517
59. Kollareddy, M., Zheleva, D., Dzubak, P., Brahmkshatriya, P. S., Lepsik, M., and Hajduch, M. (2012). Aurora kinase inhibitors: progress towards the clinic. Invest. New Drugs 30, 2411-2432. doi:10.1007/s10637-012-9798-6
60. Lock, R., Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R., et al. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 50, 1181-1189. doi:10.1002/pbc.21433
61. Lock, R. B., Carol, H., Morton, C. L., Keir, S. T., Reynolds, C. P., Kang, M. H., et al. (2012). Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr. Blood Cancer 58, 916-923. doi:10.1002/pbc.23176
62. Lugowska, I., Wozniak, W., Klepacka, T., Michalak, E., and Szamotulska, K. (2011). A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr. Blood Cancer 57, 63-68. doi:10.1002/pbc.23021
63. Malempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., et al. (2012). Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 256-262. doi:10.1200/JCO.2011.37.4355
64. Marina, N., Gebhardt, M., Teot, L., and Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9, 422-441. doi:10.1634/theoncologist.9-4-422
65. Maris, J. M., Courtright, J., Houghton, P. J., Morton, C. L., Gorlick, R., Kolb, E. A., et al. (2008a). Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 50, 581-587. doi:10.1002/pbc.21232
66. Maris, J. M., Courtright, J., Houghton, P. J., Morton, C. L., Kolb, E. A., Lock, R., et al. (2008b). Initial testing (stage 1) of sunitinib by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 51, 42-48. doi:10.1002/pbc.21535
67. Maris, J. M., Morton, C. L., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., et al. (2010). Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 55, 26-34. doi:10.1002/pbc.22430
68. Martin, J. W., Squire, J. A., and Zielenska, M. (2012). The genetics of osteosarcoma. Sarcoma 2012, 627254. doi:10.1155/2012/627254
69. Mejia-Guerrero, S., Quejada, M., Gokgoz, N., Gill, M., Parkes, R. K., Wunder, J. S., et al. (2010). Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 49, 518-525. doi:10.1002/gcc.20761
70. Miller, C. W., Aslo, A., Tsay, C., Slamon, D., Ishizaki, K., Toguchida, J., et al. (1990). Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 50, 7950-7954.
71. Mohseny, A. B., Szuhai, K., Romeo, S., Buddingh, E. P., Briaire-de Bruijn, I., de Jong, D., et al. (2009). Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J. Pathol. 219, 294-305. doi:10.1002/path.2603
72. Morton, C. L., Houghton, P. J., Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., et al. (2010). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 55, 295-303. doi:10.1002/pbc.22535
73. Morton, C. L., Maris, J. M., Keir, S. T., Gorlick, R., Kolb, E. A., Billups, C. A., et al. (2012). Combination testing of cediranib (AZD2171) against childhood cancer models by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 58, 566-571. doi:10.1002/pbc.23159
74. Mueller, F., Fuchs, B., and Kaser-Hotz, B. (2007). Comparative biology of human and canine osteosarcoma. Anticancer Res. 27, 155-164.
75. Muscal, J. A., Thompson, P. A., Horton, T. M., Ingle, A. M., Ahern, C. H., McGovern, R. M., et al. (2013). A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL0916). Pediatr. Blood Cancer 60, 390-395. doi:10.1002/pbc.24271
76. Naing, A., Kurzrock, R., Burger, A., Gupta, S., Lei, X., Busaidy, N., et al. (2012). Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res. 17, 6052-6060. doi:10.1158/1078-0432.CCR-10-2979
77. Namlos, H. M., Kresse, S. H., Muller, C. R., Henriksen, J., Holdhus, R., Saeter, G., et al. (2012). Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma 639038.
78. Nielsen, G. P., Burns, K. L., Rosenberg, A. E., and Louis, D. N. (1998). CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am. J. Pathol. 153, 159-163. doi:10.1016/S0002-9440(10)65556-3
79. Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K. P., Chawla, S. P., et al. (2011). R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29, 4541-4547. doi:10.1200/JCO.2010.34.0000
80. Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., et al. (2010). Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9, 2344-2353. doi:10.1158/1535-7163.MCT-10-0324
81. Pignochino, Y., Dell'aglio, C., Basirico, M., Capozzi, F., Soster, M., Marchio, S., et al. (2013). The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin. Cancer Res. 19, 2117-2131. doi:10.1158/1078-0432.CCR-12-2293
82. Quek, R., Wang, Q., Morgan, J. A., Shapiro, G. I., Butrynski, J. E., Ramaiya, N., et al. (2011). Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 17, 871-879. doi:10.1158/1078-0432.CCR-10-2621
83. Rettew, A. N., Young, E. D., Lev, D. C., Kleinerman, E. S., Abdul-Karim, F. W., Getty, P. J., et al. (2012). Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines. Oncogenesis 1, e34. doi:10.1038/oncsis.2012.34
84. Reynolds, C. P., Kang, M. H., Keir, S. T., Gorlick, R., Kolb, E. A., Lock, R., et al. (2011). Initial testing of lenalidomide by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 57, 606-611. doi:10.1002/pbc.22877
85. Schuetze, S. M., Zhao, L., Chugh, R., Thomas, D. G., Lucas, D. R., Metko, G., et al. (2012). Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. Eur. J. Cancer 48, 1347-1353. doi:10.1016/j.ejca.2012.03.022
86. Schwartz, G. K., Tap, W. D., Qin, L. X., Livingston, M. B., Undevia, S. D., Chmielowski, B., et al. (2013). Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 14, 371-382. doi:10.1016/S1470-2045(13)70049-4
87. Scotlandi, K. (2006). Targeted therapies in Ewing's sarcoma. Adv. Exp. Med. Biol. 587, 13-22. doi:10.1007/978-1-4020-5133-3_2
88. Shang, X., Burlingame, S. M., Okcu, M. F., Ge, N., Russell, H. V., Egler, R. A., et al. (2009). Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol. Cancer Ther. 8, 2461-2469. doi:10.1158/1535-7163.MCT-08-0857
89. Simon, T., Kohlhase, J., Wilhelm, C., Kochanek, M., De Carolis, B., and Berthold, F. (2010). Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: case report and literature review. Am. J. Med. Genet. A 152A, 1575-1579. doi:10.1002/ajmg.a.33427
90. Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., et al. (2012a). Initial testing of JNJ-26854165 (Serdemetan) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 59, 329-332. doi:10.1002/pbc.23319
91. Smith, M. A., Maris, J. M., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., et al. (2012b). Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 59, 246-253. doi:10.1002/pbc.23357
92. Smith, M. A., Morton, C. L., Phelps, D. A., Kolb, E. A., Lock, R., Carol, H., et al. (2008). Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 51, 34-41. doi:10.1002/pbc.21508
93. Spiller, S. E., Ditzler, S. H., Pullar, B. J., and Olson, J. M. (2008). Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J. Neurooncol. 87, 133-141. doi:10.1007/s11060-007-9505-1
94. Spunt, S. L., Grupp, S. A., Vik, T. A., Santana, V. M., Greenblatt, D. J., Clancy, J., et al. (2011). Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J. Clin. Oncol. 29, 2933-2940. doi:10.1200/JCO.2010.33.4649
95. Steinberg, M. (2007). Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin. Ther. 29, 2289-2308. doi:10.1016/j.clinthera.2007.11.005
96. Stone, A., Sutherland, R. L., and Musgrove, E. A. (2012). Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit. Rev. Oncog. 17, 175-198. doi:10.1615/CritRevOncog.v17.i2.40
97. Tabernero, J., Dirix, L., Schoffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., et al. (2011). A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res. 17, 6313-6321. doi:10.1158/1078-0432.CCR-11-1101
98. Tognon, C. E., and Sorensen, P. H. (2012). Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin. Ther. Targets 16, 33-48. doi:10.1517/14728222.2011.638626
99. Toretsky, J. A., Kalebic, T., Blakesley, V., LeRoith, D., and Helman, L. J. (1997). The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J. Biol. Chem. 272, 30822-30827. doi:10.1074/jbc.272.49.30822
100. van Cruijsen, H., Voest, E. E., Punt, C. J., Hoekman, K., Witteveen, P. O., Meijerink, M. R., et al. (2010). Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur. J. Cancer 46, 901-911. doi:10.1016/j.ejca.2009.12.023
101. van Maldegem, A. M., Bhosale, A., Gelderblom, H. J., Hogendoorn, P. C., and Hassan, A. B. (2012). Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment. Clin. Sarcoma Res. 2, 5. doi:10.1186/2045-3329-2-5
102. Vander Griend, R. A. (1996). Osteosarcoma and its variants. Orthop. Clin. North Am. 27, 575-581.
103. Wan, X., Mendoza, A., Khanna, C., and Helman, L. J. (2005). Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65, 2406-2411. doi:10.1158/0008-5472.CAN-04-3135
104. Wang, Y., Lipari, P., Wang, X., Hailey, J., Liang, L., Ramos, R., et al. (2010). A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol. Cancer Ther. 9, 410-418. doi:10.1158/1535-7163.MCT-09-0555
105. Wang, B., Fang, L., Zhao, H., Xiang, T., and Wang, D. (2012). MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta Biochim. Biophys. Sin. (Shanghai) 44, 685-691. doi:10.1093/abbs/gms053
106. Widemann, B. C., Kim, A., Fox, E., Baruchel, S., Adamson, P. C., Ingle, A. M., et al. (2012). A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium Report. Clin. Cancer Res. 18, 6011-6022.
107. Wong, F. L., Boice, J. D. Jr., Abramson, D. H., Tarone, R. E., Kleinerman, R. A., Stovall, M., et al. (1997). Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278, 1262-1267. doi:10.1001/jama.278.15.1262
108. Yamaguchi, T., Toguchida, J., Yamamuro, T., Kotoura, Y., Takada, N., Kawaguchi, N., et al. (1992). Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res. 52, 2419-2423.
109. Yu, Y., Luk, F., Yang, J. L., and Walsh, W. R. (2011). Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res. 31, 1147-1152.
110. Yung, W. K. A. (2010). Review of the complexities of the PI3K/mTOR pathway presages similar handling of other critical topics. Neuro-oncology 12, 763-764. doi:10.1093/neuonc/noq083